Risk of stroke and other adverse outcomes in patients with perioperative atrial fibrillation 1 year after non-cardiac surgery.

AIMS To determine the 1-year risk of stroke and other adverse outcomes in patients with a new diagnosis of perioperative atrial fibrillation (POAF) after non-cardiac surgery. METHODS AND RESULTS The PeriOperative ISchemic Evaluation (POISE)-1 trial evaluated the effects of metoprolol vs. placebo in 8351 patients, and POISE-2 compared the effect of aspirin vs. placebo, and clonidine vs. placebo in 10 010 patients. These trials included patients with, or at risk of, cardiovascular disease who were undergoing non-cardiac surgery. For the purpose of this study, we combined the POISE datasets, excluding 244 patients who were in atrial fibrillation (AF) at the time of randomization. Perioperative atrial fibrillation was defined as new AF that occurred within 30 days after surgery. Our primary outcome was the incidence of stroke at 1 year of follow-up; secondary outcomes were mortality and myocardial infarction (MI). We compared outcomes among patients with and without POAF using multivariable adjusted Cox proportional hazards models. Among 18 117 patients (mean age 69 years, 57.4% male), 404 had POAF (2.2%). The stroke incidence 1 year after surgery was 5.58 vs. 1.54 per 100 patient-years in patients with and without POAF, adjusted hazard ratio (aHR) 3.43, 95% confidence interval (CI) 2.00-5.90; P < 0.001. Patients with POAF also had an increased risk of death (incidence 31.37 vs. 9.34; aHR 2.51, 95% CI 2.01-3.14; P < 0.001) and MI (incidence 26.20 vs. 8.23; aHR 5.10, 95% CI 3.91-6.64; P < 0.001). CONCLUSION Patients with POAF have a significantly increased risk of stroke, MI, and death at 1 year. Intervention studies are needed to evaluate risk reduction strategies in this high-risk population.

[1]  L. Køber,et al.  Risk of Thromboembolism Associated With Atrial Fibrillation Following Noncardiac Surgery. , 2018, Journal of the American College of Cardiology.

[2]  G. Guyatt,et al.  Dabigatran in patients with myocardial injury after non-cardiac surgery (MANAGE): an international, randomised, placebo-controlled trial , 2018, The Lancet.

[3]  S. Connolly,et al.  Rivaroxaban for Stroke Prevention after Embolic Stroke of Undetermined Source , 2018, The New England journal of medicine.

[4]  D. Cook,et al.  Predictors, Prognosis, and Management of New Clinically Important Atrial Fibrillation After Noncardiac Surgery: A Prospective Cohort Study , 2017, Anesthesia and analgesia.

[5]  P. Kirchhof,et al.  2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. , 2016, European heart journal.

[6]  J. Healey,et al.  Perioperative atrial fibrillation and the long-term risk of ischemic stroke. , 2014, JAMA.

[7]  P. Devereaux.  Rationale and design of the PeriOperative ISchemic Evaluation-2 (POISE-2) trial: an international 2 × 2 factorial randomized controlled trial of acetyl-salicylic acid vs. placebo and clonidine vs. placebo in patients undergoing noncardiac surgery. , 2014, American heart journal.

[8]  G. Guyatt,et al.  Clonidine in patients undergoing noncardiac surgery. , 2014, The New England journal of medicine.

[9]  G. Guyatt,et al.  Aspirin in patients undergoing noncardiac surgery. , 2014, The New England journal of medicine.

[10]  Alexander Parkhomenko,et al.  Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials , 2014, The Lancet.

[11]  S. Kalantarian,et al.  Cognitive Impairment Associated With Atrial Fibrillation , 2013, Annals of Internal Medicine.

[12]  James Floyd,et al.  A systematic review of validated methods for identifying atrial fibrillation using administrative data , 2012, Pharmacoepidemiology and drug safety.

[13]  C. Albert,et al.  Risk of death and cardiovascular events in initially healthy women with new-onset atrial fibrillation. , 2011, JAMA.

[14]  Shuang Wang,et al.  Perioperative Acute Ischemic Stroke in Noncardiac and Nonvascular Surgery: Incidence, Risk Factors, and Outcomes , 2009, Anesthesiology.

[15]  Denis Xavier,et al.  Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial): a randomised controlled trial , 2008, The Lancet.

[16]  R. de Caterina,et al.  Risks and Benefits of Oral Anticoagulation Compared With Clopidogrel Plus Aspirin in Patients With Atrial Fibrillation According to Stroke Risk: The Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE-W) , 2008, Stroke.

[17]  M. Aguilar,et al.  Meta-analysis: Antithrombotic Therapy to Prevent Stroke in Patients Who Have Nonvalvular Atrial Fibrillation , 2007, Annals of Internal Medicine.

[18]  P. Wolf,et al.  Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. , 1991, Stroke.

[19]  N. Breslow,et al.  Statistical methods in cancer research. Volume II--The design and analysis of cohort studies. , 1987, IARC scientific publications.